5:34 PM
 | 
Mar 26, 2013
 |  BC Extra  |  Company News

Lundbeck, Otsuka add AD compound to 2011 deal

H. Lundbeck A/S (CSE:LUN) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) co-development and co-commercialization rights to Lu AE58054 in the U.S., Canada, East Asia, major European countries and Nordic countries. The selective serotonin (5-HT6) receptor antagonist...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >